Andrew W. Hahn

Andrew W. Hahn is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on prostate cancer, genitourinary malignancies, and cancer pharmacology, with particular emphasis on the influence of body composition and cardiometabolic health on treatment outcomes. His recent work investigates testosterone levels and disease progression in active surveillance, the efficacy of chemotherapy in aggressive variant prostate cancer, and combination immunotherapy with VEGFR-TKIs for advanced renal cell carcinoma. He has led phase II trials examining nivolumab, ipilimumab, and cabozantinib in brain metastases from renal cell carcinoma and contributes to expert consensus on evolving prostate cancer strategies.